CWLXF C21 Investments Inc. Annual reports only
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 831609 · Fiscal year ends 03/31
Financial factors as of 2026-03-31 (FY2026), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY8.3%
TTM net income YoY18.3%
TTM EPS YoY0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin41.7%
Operating margin7.0%
Net margin-9.9%
FCF margin3.4%
EBITDA margin12.4%
Returns
ROE-12.0%
ROA-5.8%
ROIC (approx.)4.6%
Asset turnover0.59x
Leverage & solvency
Liabilities / assets53.3%
Debt / equity0.00x
Current ratio1.30x
Interest coverage12.17x
Cash quality & payout
Operating cash flow / net income-0.42x
Accruals ratio-8.3%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20262026-03-31 | FY20252025-03-31 | FY20242024-01-31 | FY20232023-01-31 | FY20222022-01-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $32.61M | $30.12M | $28.29M | $28.89M | $32.98M |
| Cost of revenue | $19.01M | $17.56M | $17.14M | $15.49M | $14.17M |
| Gross profit | $13.61M | $12.56M | $11.15M | $13.40M | $18.81M |
| SG&A expense | $11.33M | $11.28M | $9.68M | $9.45M | $9.06M |
| Operating income | $2.28M | $1.28M | $1.47M | $3.96M | $9.75M |
| Interest expense | $187,241 | $293,675 | $35,210 | $456,691 | $1.08M |
| Pretax income | $1.38M | $394,921 | $258,657 | $4.19M | $17.13M |
| Income tax | $4.61M | $4.15M | $3.48M | $2.81M | $4.93M |
| Net income | -$3.24M | -$3.97M | -$3.31M | $293,211 | $9.95M |
| EBITDA | $4.06M | $2.99M | $2.88M | $5.80M | $11.57M |
| EPS (basic) | -0.03 | -0.03 | -0.03 | 0.00 | 0.08 |
| EPS (diluted) | -0.03 | -0.03 | -0.03 | 0.00 | 0.08 |
| Weighted avg. shares (diluted) | 118.47M | 120.59M | 122.88M | 122.88M | 121.14M |
| Balance sheet | |||||
| Cash & equivalents | $2.23M | $2.63M | $2.41M | $1.89M | $3.07M |
| Receivables | $57,084 | $124,827 | $189,192 | $401,476 | $198,478 |
| Inventory | $4.59M | $4.05M | $2.71M | $4.17M | $4.05M |
| Current assets | $8.31M | $7.50M | $7.24M | $8.60M | $10.28M |
| PP&E, net | $2.30M | $2.67M | $3.43M | $4.69M | $4.87M |
| Goodwill | $28.54M | $28.54M | $28.54M | $28.54M | $28.54M |
| Intangibles | $6.41M | $8.09M | $6.48M | $7.89M | $9.22M |
| Total assets | $54.42M | $57.00M | $54.53M | $58.31M | $61.84M |
| Current liabilities | $6.39M | $7.96M | $14.17M | $14.97M | $15.97M |
| Total liabilities | $28.99M | $28.32M | $23.48M | $24.00M | $28.12M |
| Shareholders' equity | $25.43M | $28.68M | $31.05M | $34.32M | $33.73M |
| Shares outstanding | 117.84M | 118.00M | 120.05M | 120.05M | 120.05M |
| Cash flow statement | |||||
| Operating cash flow | $1.36M | $1.37M | $3.26M | $5.97M | $8.44M |
| Capital expenditure | $244,838 | $406,733 | $521,579 | $442,285 | $2.56M |
| Free cash flow | $1.12M | $958,920 | $2.74M | $5.53M | $5.88M |
| Investing cash flow | -$219,838 | -$3.45M | -$121,579 | -$442,285 | -$2.56M |
| Financing cash flow | -$1.54M | $1.67M | -$2.65M | -$6.63M | -$7.74M |
| Depreciation & amortization | $1.78M | $1.71M | $1.41M | $1.84M | $1.82M |
| Stock-based compensation | $236,779 | $849,559 | $22,128 | $209,441 | $366,469 |
| Share buybacks | $103,034 | $276,730 | $0 | — | — |
Free plan shows the latest 5 periods; Pro shows all 9 🔒
· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.